These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1149 related articles for article (PubMed ID: 6467174)

  • 41. Pharmacokinetics of vindesine and vincristine in humans.
    Owellen RJ; Root MA; Hains FO
    Cancer Res; 1977 Aug; 37(8 Pt 1):2603-7. PubMed ID: 872088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of alpha-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice, EMT6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats.
    Bartholeyns J; Koch-Weser J
    Cancer Res; 1981 Dec; 41(12 Pt 1):5158-61. PubMed ID: 6796266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines.
    Tolis C; Photiou A; Camplejohn RS; Retsas S
    Anticancer Res; 1993; 13(1):161-6. PubMed ID: 8476208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
    Dorr RT; Alberts DS
    J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular uptake and tubulin binding properties of four Vinca alkaloids.
    Singer WD; Himes RH
    Biochem Pharmacol; 1992 Feb; 43(3):545-51. PubMed ID: 1540212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties.
    Irimura T; Gonzalez R; Nicolson GL
    Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases.
    Tsuruo T; Fidler IJ
    Cancer Res; 1981 Aug; 41(8):3058-64. PubMed ID: 7248962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.
    Hill BT; Whelan RD
    Cancer Chemother Pharmacol; 1982; 8(2):163-9. PubMed ID: 7105380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.
    Binet S; Fellous A; Lataste H; Krikorian A; Couzinier JP; Meininger V
    Semin Oncol; 1989 Apr; 16(2 Suppl 4):5-8. PubMed ID: 2652320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
    Ono M; Tanaka N
    In Vivo; 1997; 11(3):233-41. PubMed ID: 9239517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
    Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis.
    McGown AT; Poppitt DG; Swindell R; Fox BW
    Cancer Chemother Pharmacol; 1984; 13(1):47-53. PubMed ID: 6733842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.
    Tsuruo T; Iida H; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1983 Feb; 43(2):808-13. PubMed ID: 6848194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
    Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dexamethasone, medroxyprogesterone acetate, and vindesine modulation of human malignant melanoma growth in soft agar.
    Bojar H; Fabry W
    Anticancer Res; 1985; 5(2):189-92. PubMed ID: 3994310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vinca-23-oyl amino acid derivatives: as new anticancer agents (review).
    Bhushana Rao KS; Collard MP; Trouet A
    Anticancer Res; 1985; 5(4):379-86. PubMed ID: 3898995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of in vitro and in vivo effects of vincristine and vindesine on leukemic cells from patients with chronic granulocytic leukemia in blast crisis.
    Theodorakis ME; Goldberg J
    Leuk Res; 1984; 8(6):1065-71. PubMed ID: 6595480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of vinblastine, vincristine, and vindesine on neutrophil phagocytosis and iodination.
    Chohan V; Lowenthal RM
    Cancer Treat Rep; 1982 Mar; 66(3):505-8. PubMed ID: 7037181
    [No Abstract]   [Full Text] [Related]  

  • 60. Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.
    Attaoua C; Vincent LA; Abdel Jaoued A; Hadj-Kaddour K; Baï Q; De Vos J; Vian L; Cuq P
    Fundam Clin Pharmacol; 2015 Feb; 29(1):62-71. PubMed ID: 25283245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.